MYOMO, INC.: insider trades · United States · SEC (Form 4)

About MYOMO, INC.

Myomo, Inc. is a U.S.-based medical technology and wearable medical robotics company listed on NYSE American (within the broader NYSE/NASDAQ U.S. listed universe for international investors). The company is headquartered in Burlington, Massachusetts, United States, and markets the MyoPro® product line, a lightweight, non-invasive powered orthosis for the arm and hand. MyoPro is designed for individuals with upper-limb paralysis or weakness caused by stroke, spinal cord injury, nerve injury such as brachial plexus injury, and other neuromuscular disorders. Myomo says the product is built on patented technology developed at MIT and Harvard Medical School and uses non-invasive sensors to detect a patient’s own neurological signals and translate them into assisted movement. ([myomo.com](https://myomo.com/about-myomo/?utm_source=openai)) Founded in the mid-2000s, Myomo has evolved from an R&D-driven medtech business into a commercial-stage company focused on neuromuscular rehabilitation and upper-extremity functional restoration. Its business model centers on clinical referrals, orthotics and prosthetics (O&P) providers, rehabilitation centers, and hospital networks, rather than direct-to-consumer sales. The company states that MyoPro is fitted and delivered through a nationwide network of O&P practices across the U.S., supported by sales and clinical professionals spread across the country. Myomo also maintains an international sales channel, which it highlighted as a source of record fourth-quarter revenue in 2025. ([myomo.com](https://myomo.com/about-myomo/?utm_source=openai)) From a competitive standpoint, Myomo occupies a niche position in assistive medical robotics. The category is specialized, clinically intensive, and relatively difficult to penetrate because it requires regulatory clearance, clinician training, reimbursement execution, and evidence generation. Myomo’s differentiation lies in being one of the few companies focused specifically on powered upper-limb orthoses for neurologically impaired patients. The company emphasizes clinical referrals from well-known institutions such as Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, Kennedy Krieger Institute, Loma Linda Medical Center, and multiple Veterans Health Administration hospitals. It also says more than 600 patients have used MyoPro, underscoring a meaningful installed base in a still-emerging market. ([myomo.com](https://myomo.com/about-myomo/?utm_source=openai)) Recent operating updates suggest improving commercial momentum. Myomo reported first-quarter 2025 revenue of $9.8 million and a record addition to its patient pipeline; second-quarter 2025 revenue of $9.7 million with 816 patients added to the pipeline; third-quarter 2025 revenue of $10.1 million with 229 authorizations and orders; and fourth-quarter 2025 revenue of $11.4 million, bringing full-year 2025 revenue to $40.9 million. The company also introduced 2026 revenue guidance of $43 million to $46 million and noted that 42% of fourth-quarter revenue came from recurring patient sources. Management has increasingly stressed growth in the O&P channel, broader referral pathways, and a shift toward lower-cost recurring patient acquisition. ([myomo.com](https://myomo.com/myomo-reports-first-quarter-2025-financial-and-operating-results/?utm_source=openai))